% | $
Quotes you view appear here for quick access.

VeriFone Systems, Inc. Message Board

holeinonein2002 10 posts  |  Last Activity: Nov 20, 2015 2:41 PM Member since: Aug 4, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • holeinonein2002 by holeinonein2002 Nov 20, 2015 2:41 PM Flag

    What the hell happened ?

  • AMAG. "we'll positioned for potential upside in 2016"

    Sentiment: Strong Buy

  • Robert Griffin and William Morgan...Hope you make a killing

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Nov 12, 2015 2:04 PM Flag

    Price target revised to $6.00....100% return

    Sentiment: Strong Buy

  • Investment opinion. We are reiterating our Buy rating of Celsion Corporation, and a 12-month price target of $8, based on a comparables analysis of similarly staged biotechnology companies. Yesterday, Celsion presented preclinical data that demonstrated enhanced tumoricidal activity can be achieved by pairing GEN-1 immunotherapy with Avastin and Doxil, the current standard of care (SOC) for Pt-refractory ovarian cancer. Notably, the triple combination yielded a higher reduction in mean tumor burden relative to an untreated control group compared to that achieved with Avastin + high dose Doxil (98% vs. 88%), and 75% of animals in the triple combination group presented no visible tumors by the end of the study. We believe these results underscore the rationale for the company’s development strategy for GEN-1 in Pt-resistant ovarian cancer and support Celsion’s planned Phase 1/2 study of the triple combination in Pt-resistant ovarian cancer, expected to initiate in 1H16. With both immuno-oncology and RNA-delivery assets taking center stage, and $25M cash (expected to sustain operations until mid-2016), we believe Celsion represents an attractive player with significant upside for the long term, risk tolerant investor.

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Oct 12, 2015 11:56 AM Flag


    Ovarian cancer (OC) is the eighth-most diagnosed cancer among women, and the 17th-most common cancer overall. The disease has an estimated annual incidence of 225,000 new cases worldwide; approximately 100,000 of these new cases arise in developed countries, including 22,000 in the United States. OC is the fifth-most deadly cancer among women, comprising 5% of total deaths in women. The 5-year survival rate for all stages of OC is 45%, and is dramatically reduced when the cancer is not localized. Moreover, while women with localized OC are generally eligible for potentially curative surgery, fewer than 15% of women with OC are diagnosed while the cancer is still at a localized stage.

    In most cases, OC is diagnosed after the disease has metastasized (spread) to regional or distant sites. Such cases are generally treated with systemic chemotherapy, usually via intravenous (IV) injection or oral therapy, although some women – particularly those with abdominal metastases – may receive intraperitoneal (IP) chemotherapy, whereby the drugs are injected through a catheter directly into the abdominal cavity.

    GEN-1, an immunotherapy consisting of an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, is administered via the IP route, making it a potentially suitable adjunct to any IV, IP, or oral therapeutic regimen for OC. It is designed to target cancer cells that are resistant to standard chemotherapy by recruiting the immune system to induce powerful anti-cancer responses. The combination of GEN-1 and Doxil® (PEGylated liposomal doxorubicin) is currently being investigated a Phase Ib trial in patients with platinum-resistant OC.

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Oct 2, 2015 10:54 AM Flag

    Balance sheet, PE ratio, backlog, and analyst recomdations don't mean #$%$. When the big boys leave the party the trend takes forever to turn around. Which probably means we are at or near a bottom.

    Sentiment: Buy

  • Among the smaller-cap companies, Celsion Corp. (CLSN:NASDAQ) is a very interesting company. It has a market cap of only about $46M, but its range of clinical trials exceeds that of companies with comparable capitalization.

    "I think we're in a short-term bubble, but not a biotech bubble."
    It's rare you meet a value play in biotech that has a good management team that says what it will do and then does it, putting forward science that is exceptionally well validated in peer-reviewed literature. The Celsion team does that.

    Celsion probably will publish results in a leading peer-reviewed journal analyzing the result of new, follow-up trials of one of its drugs that failed in Phase 3, ThermoDox (liposome-encapsulated doxorubicin). If any of those trials succeeds, Celsion could easily gain a market cap of $1 billion ($1B). That's probably two-and-a-half years in the future, and there's still a long way to go. Based on the range and breadth of its programs, Celsion currently should have a market cap in the hundreds of millions of dollars.

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Sep 30, 2015 9:41 AM Flag

    Should get a little positive fallout for Trinity

    Sentiment: Strong Buy

  • holeinonein2002 by holeinonein2002 Sep 30, 2015 9:16 AM Flag

    Celsion'so GEN-1 plus Avastin or Doxil is a exciting development for ovarian cancer patients as well as shareholders. According to Dr.Thanker at Washington U. School of Medicine "In preclinical and clinical studies performed to date,Gen-1 has demonstrated good safety and impressive immune system stimulation and activity"

    Sentiment: Strong Buy

28.79+0.03(+0.10%)Nov 27 1:02 PMEST